In-Depth Characterization of a Pro-Antibody–Drug Conjugate by LC–MS

详细信息    查看全文

• 作者：Boning Liu ; Huaizu Guo ; Junjie Zhang ; Jingya Xue ; Yun Yang ; Ting Qin ; Jin Xu ; Qingcheng Guo ; Dapeng Zhang ; Weizhu Qian ; Bohua Li ; Sheng Hou ; Jianxin Dai ; Yajun Guo ; Hao Wang
• 刊名：Molecular Pharmaceutics
• 出版年：2016
• 出版时间：August 1, 2016
• 年：2016
• 卷：13
• 期：8
• 页码：2702-2710
• 全文大小：452K
• 年卷期：0
• ISSN：1543-8392

文摘

Pro-antibody–drug conjugate (PDC) is a hybrid structural format of immunoconjugate, where the structural complexity of pro-antibody and intrinsic heterogeneity of ADCs impose a prominent analytical challenge to the in-depth characterization of PDCs. In the present study, we successfully prepared and characterized PanP–DM1 as a model of PDCs, which is an anti-EGFR pro-antibody following conjugation with DM1 at lysine residues. The drug-to-antibody ratio (DAR) of PanP–DM1 was determined by LC–MS after deglycosylation, and verified by UV/vis spectroscopy. Following reduction or IdeS digestion, the pro-antibody fragments linked with DM1 were investigated by middle-down mass spectrometry. Furthermore, more than 20 modified lysine conjugation sites were determined by peptide mapping after trypsin digestion. Additionally, more than ten glycoforms of PanP–DM1 were also identified and quantified. In summary, critical quality attributes (CQAs) of PDCs including DAR, drug load distribution, and conjugation sites were fully characterized, which would contribute to the development of other PDCs for cancer treatment.